Spectral Molecular Imaging Names Veteran NASA Physicist and Biomedical Imaging Expert Gregory Bearman as Chief Scientist

Spectral Molecular Imaging, a wholly-owned subsidiary of Cascade Technologies, Inc. (OTCBB: CSDT), has appointed Gregory Bearman, Ph.D., to the position of Chief Scientist, where he will guide development of a range of imaging devices for the earlier detection of cancer and other major disease, based on the Company's proprietary optical imaging technologies.

Dr. Bearman is a leader in digital and spectral imaging for biomedical uses, planetary exploration and even archeology, pioneering the use of spectral imaging to study some of the world’s most important artifacts, including the Dead Sea Scrolls.

Trained in atomic physics, Dr. Bearman worked for nearly 30 years (1979-2008) at NASA’s Jet Propulsion Laboratory in Pasadena, where he was a Principal Scientist, managing a group that developed new technologies and instruments for remote sensing and planetary surface exploration, with an emphasis on developing new sensors and spectral imagers.

Dr. Bearman has started two companies, one that worked with high sensitivity biological and chemical sensors and a second that develops and licenses fast (snapshot) spectral imagers for a variety of applications. He has also consulted for numerous businesses on matters relating to intellectual property, marketing, and product development. He has been a visiting scientist at St. Luke’s Hospital in Houston and Cedars-Sinai Medical Center in Los Angeles, and has an adjunct appointment in the Ophthalmology Department at the USC Keck School of Medicine. He is a member of the editorial board of the Journal of Biomedical Optics and for many years was an organizer of the annual SPIE conference on Biomedical Imaging Spectroscopy.

“Greg brings Spectral Molecular Imaging invaluable experience as a biomedical optics expert of international recognition, as well as a manager and executive with a proven track record of applying technology to develop real-world solutions and products,” said Daniel L. Farkas, Ph.D., Chairman of Spectral Molecular Imaging. “His background in spectral imaging technology, along with his experience in business, makes him an ideal choice for the position of Chief Scientist.”

Dr. Bearman’s recent biomedical research includes clinical applications of retinal imaging spectroscopy in collaboration with Doheny Eye Institute and USC Keck School of Medicine. He has seven patents and more than 100 publications.

Spectral Molecular Imaging is applying proprietary technology in the development of a range of medical imaging products to enable earlier and more accurate detection and diagnosis of skin cancers such as melanoma, as well as other diseases. The Company’s non-invasive imaging technology is expected to significantly improve patient outcomes while lowering health care costs.

About Spectral Molecular Imaging

Spectral Molecular Imaging, Inc., a wholly-owned subsidiary of Cascade Technologies, Inc., is a development-stage, medical imaging device company. Application of SMI’s proprietary spectral-optical imaging technology—originally developed for satellite reconnaissance—is expected to advance the diagnoses of cancer and precancerous conditions. SMI is developing non-invasive imaging systems using its patented technology for improved clinical diagnostics, primarily in the field of cancer pathology. SMI’s devices utilize high-resolution imaging, identification, and analysis of certain molecular, cellular, and tissue features via patented spectral-imaging approaches. We also intend to provide services related to our primary products, including software modules and maintenance services, and to develop optical diagnostic products that operate in conjunction with surgical and/or evaluation procedures in real time. Our technology is expected to enable early detection and more reliable diagnosis of various diseases, including skin cancers such as melanoma, Barrett’s esophagus (a condition caused by chronic acid reflux that can lead to esophageal cancer) and lung cancer. The development of this technology is expected to significantly improve long-term patient outcomes while substantially reducing overall costs for the healthcare system. For more information, please visit http://www.spectralmi.com.

Forward-Looking Statements

The content of this news announcement contains or may contain certain "forward-looking statements" within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to significant risks and uncertainties, including those detailed in filings made by Cascade Technologies, Inc., SMI's parent, with the Securities and Exchange Commission. Forward-looking statements may include, without limitation, statements regarding SMI's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects", "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. These statements are based upon the current beliefs and expectations of SMI's management; however, actual results, including, without limitation, actual sales and other financial results, may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve risks and uncertainties that are subject to change based on various factors, many of which are beyond SMI's control.